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 ABSTRACT 
 
Initially considered as a macrophage inhibitor (macrophage inhibitory cytokine-1), growth 
differentiation factor 15 (GDF-15) has been identified as a pleiotropic protein that plays key 
roles in prenatal development, in inflammation, in the regulation of cellular responses to stress 
signals, and in tissue repair after acute injuries in adult life. Multiple studies have revealed 
that GDF-15, a distant member of the transforming growth factor β (TGF-β) family, acts as a 
critical hormone to regulate lipid and carbohydrate metabolism. Besides its role in the 
tumorigenesis and diagnosis of cancer, serum GDF-15 concentrations reflect a “systemic 
response” and are predictive of all-cause mortality. Based on the knowledge from animal 
studies of its involvement in multiple inflammatory processes, we will focus in this review on 
the current clinical data on GDF-15 as a biomarker for cardiovascular disease, kidney disease, 
liver disease, the metabolic syndrome, diabetes mellitus and sepsis. 
 
KEYWORDS: biomarker; growth differentiation factor 15; macrophage inhibitory cytokine-
1; transforming growth factor-β 
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 Abbreviations and glossary:  
ACD, anemia of chronic disease 
AKI: acute kidney injury 
BMI: body mass index 
CHOP: C/EBP-homologous protein 
CKD: chronic kidney disease 
C-PROBE: Clinical Phenotyping and Resource Biobank 
CRP: C-reactive protein 
DAN-MONICA: Danish-Multinational MONitoring of trends and determinants in 
Cardiovascular disease 
ECM: extracellular matrix 
eGFR: estimated glomerular filtration rate 
ER: endoplasmic reticulum 
EURAGEDIC: European Rational Approach for the Genetics of Diabetic Complications 
GDF-15: growth differentation factor 15 
GDNF: glial cell-derived neurotrophic factor 
GFRAL: glial cell-derived neurotrophic factor receptor alpha-like 
HCV: hepatitis C virus 
HFmrEF: heart failure with midrange ejection fraction 
HFpEF: heart failure with preserved ejection fraction 
HFrEF: heart failure with a reduced ejection fraction 
HOMA-IR: homeostasis model assessment of insulin resistance 
hs-TnT: high sensitivity troponin T 
IDA: iron deficiency anemia 
IL: interleukin 
MADRAD: Malnutrition, Diet, and Racial Disparities in Chronic Kidney Disease 
NAFLD: non-alcoholic fatty liver disease 
NASH: non-alcoholic steatohepatitis 
NSTEMI. non-ST elevation myocardial infarction  
NT-proBNP: N-terminal pro-brain natriuretic peptide 
ORIGIN: Outcome Reduction with Initial Glargine Intervention 
PCOS: polycystic ovary syndrome 
PCSK: proprotein convertase, subtilisin/kexin-type 
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 PIVUS: Prospective Investigation of the Vasculature in Uppsala Seniors 
PREVEND: Prevention of Renal and Vascular Endstage Disease 
SKS: Seattle Kidney Study 
STEMI, ST elevation myocardial infarction  
Sun-MACRO: sulodexide macroalbuminuria 
TGF-β: transforming growth factor β 
ULSAM: Uppsala Longitudinal Study of Adult Men 
XENDOS: XENical in the prevention of Diabetes in Obese subjects 
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 Introduction 
 
Growth differentiation factor 15 (GDF-15), first identified in 1997 as macrophage inhibitory 
cytokine-1
1
, and also known as prostate-derived factor, placental transforming growth factor-
β, placental bone morphogenetic protein  and non-steroidal anti-inflammatory drug-activated 
gene-1, is a stress-responsive member of the transforming growth factor β (TGF-β) cytokine 
superfamily. The diversity of its nomenclature reflects the pleiotropic nature of this protein, 
with roles in inflammation, metabolism and cancer
2
. The TGF-β superfamily comprises a 
wide number of structurally and functionally related growth and differentiation factors that 
provide critical roles during embryogenesis, maintenance of tissue homeostasis, and the stress 
response program of cells after cellular injury. GDF-15 is characterized by a wide tissue 
distribution pattern with  high expression in the prostate
3,4
 and placenta
5,6
. It has also been 
detected in the heart
7
, intestine
4
, liver
8
, kidney
3
, pancreas
3
, colon
9
, lung
10
, brain
4
 and skeletal 
muscle
10
. It acts as a multifunctional cytokine, controlling numerous physiological and 
pathological processes
1,11
. Acting on the hypothalamus and hindbrain, GDF-15 is a key 
inducer of cancer-related anorexia and weight loss
12
. Moreover, GDF-15 plays an important 
role in the physiological regulation of energy intake and expenditure, with a more pronounced 
effect in women than in men
13
. Although several studies suggest antitumoral activity
10,14,15
, 
the protumoral effects of GDF-15 appear to prevail
16-19
. Interest has also arisen in the use of 
GDF-15 as a biomarker for diagnosis, prognosis and/or risk stratification of various patient 
populations. We will focus in the present paper on the available clinical data on GDF-15 as a 
biomarker in cardiovascular disease, kidney disease, liver disease, the metabolic syndrome, 
diabetes mellitus and sepsis.  
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 General characteristics 
GDF-15 is synthesized as a 40-kDa propeptide with an N-terminal propeptide and a C-
terminal mature GDF-15 domain. Before transport to the Golgi, disulfide-linked dimerization 
of the precursor takes place in the endoplasmic reticulum (ER). The dimeric precursor is then 
cleaved by proprotein convertase [three members of the proprotein convertase, 
subtilisin/kexin-type (PCSK) family, namely PCSK3, PCSK5 and PCSK6] to release a 24.5-
kDa active circulating dimeric protein, which is secreted into the extracellular medium
1,20,21
. 
In tumor cells, unprocessed or partially processed forms of GDF-15 may also be secreted and 
these forms remain bound to the extracellular matrix (ECM) and undergo extracellular 
processing
22
. The human GDF-15 gene is located on chromosome 19 in the region p13.1-13.2 
(Figure 1)
1,20
. A single transmembrane cell surface protein, glial cell-derived neurotrophic 
factor (GDNF) receptor alpha-like (GFRAL), has been identified as a high affinity brainstem-
restricted receptor of GDF-15 that requires interaction with the co-receptor RET, a receptor 
tyrosine kinase that is similar to other members of the GDNF receptor family
23-25
. Animal 
studies have suggested that GDF-15 may undergo hepatic clearance via scavenger receptors 
expressed on liver sinusoidal cells
26
. 
     Under resting conditions, restricted production of GDF-15 has been observed in 
myocardium, lung, kidney, brain, liver and the intestine but not in the placenta
1,11
. Serum 
GDF-15 concentrations are very high during pregnancy
27
, whereas low concentrations are 
associated with increased risk of miscarriage
28
. GDF-15 is localized at the maternofetal 
interface and may promote the survival of the fetus by suppressing the maternal production of 
proinflammatory cytokines within the uterus and/or allowing immunotolerance of the 
semiallogeneic fetus
27
. Higher serum GDF-15 concentrations have been reported in acute and 
chronic inflammation, anemia and bleeding, atrial fibrillation, cachexia, chronic kidney 
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 disease (CKD), current smoking, diabetes mellitus, metabolic syndrome, heart failure, solid 
cancers, terminal illness, and vascular disease
29
. 
     The expression of GDF-15 may be increased in response to diverse signals (Figure 1) such 
as oxygen deprivation (e.g. oxidative stress, hypoxia and anoxia); inflammation and acute 
tissue injuries [e.g. by proinflammatory cytokines such as tumor necrosis factor-alpha, 
interleukin-1 beta (IL, interleukin), IL-6, macrophage colony-stimulating factor]; short-
wavelength light exposure; telomere erosion; oncogene activation [e.g. by epidermal growth 
factor receptor-1); tumor suppressor protein; nuclear factor kappa-light-chain-enhancer of 
activated B cells; hypoxia-inducible factor 1-alpha; and some drugs (e.g. non-steroidal anti-
inflammatory drugs, etoposide, …)30,31. Although the exact working mechanisms are not yet 
clarified, GDF-15 may function as an autocrine, anti-inflammatory and cellular repair factor 
that is secreted in quantities proportional to acute and chronic tissue injury
1,30
.  
     In a meta-analysis
32
 of genome-wide association studies, a locus on chromosome 19 that 
contains the PGPEP1, the GDF-15 and the LRRC25 genes was shown to contribute to the 
regulation of the GDF-15 concentration in human blood. Several other genes may be involved 
in the regulation of blood GDF-15 concentration, including B3GALT6 (chromosome 1), SDF4 
(chromosome 1) and TNFRSF4 (chromosome 1) genes, and the MIR3189 gene (chromosome 
19); as well, the COPI-mediated anterograde transport pathway may be involved. 
     The concentration of GDF-15 in human serum and plasma has been measured using a 
research enzyme-linked immunosorbent assay
27
, an enzyme-linked immunosorbent assay 
using antibodies from R&D Systems (Quantikine
®
, R&D Systems, Abingdon, Oxfordshire, 
UK)
33
, a research immunoradiometric assay
34
, a Luminex sandwich assay (Alere Inc, 
Waltham, MA)
35
, a fully automated electrochemiluminescence immunoassay (Elecsys
®
, 
Roche Diagnostics,  Penzberg, Germany)
36
 and a liquid chromatography electrospray 
ionization mass spectrometry
37
.  
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 General population (Table 1) 
In healthy subjects, a serum GDF-15 concentration of approximately 200-1200 ng/L has been 
observed
38
; the levels are influenced by polymorphisms of the GDF-15 gene
39-43
. Age-
dependent reference values for circulating GDF-15 derived from an evidently healthy 
population have established a framework for risk-stratification studies
44
. Serum GDF-15 
concentrations are inversely correlated with the body mass index (BMI), as demonstrated in a 
cohort of 72 monozygotic non-obese twin pairs. A bimodal diurnal variation of GDF-15 
expression has been described (with a peak around midnight and nadir around noon in most 
subjects), which can alter serum GDF-15 levels by about plus or minus 10%, whereas there is 
little day-to-day variation
45
. An increase in serum GDF-15 concentrations is observed with 
aging, reflecting that both cardiovascular and other biological processes are closely related to 
longevity, and with smoking
46
. No sex differences have been noted
34
.  
     Several studies have investigated the potential value of GDF-15 as a biomarker in the 
general population, “from young to old”. In the Dallas Heart Study, plasma GDF-15 was 
independently associated with subclinical coronary atherosclerosis and mortality in a young 
multiethnic population, even after adjustment for traditional risk factors, renal function and 
left ventricle mass/body surface area
47
. The DAN-MONICA (Danish-Multinational 
MONitoring of trends and determinants in Cardiovascular disease) cohort illustrated the 
predictive role of repeated blood GDF-15 measurement for death due to coronary heart 
disease and the occurrence of heart failure in the general population
48
. 
     A small prospective, nested, case-control study in initially healthy middle-aged women 
participating in the Women’s Health Study with a 4-year follow-up showed that participants 
with the highest baseline blood GDF-15 concentrations had a 3-fold higher risk of developing 
future cardiovascular events (myocardial infarction, thromboembolic stroke or cardiovascular 
death), even after adjustment for C-reactive protein (CRP)
49
. In the Framingham Heart Study, 
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 a distinct prognostic value of GDF-15 for death, cardiovascular events and heart failure in 
apparently healthy individuals was also demonstrated
50,51
. Moreover the Framingham 
Offspring Study, including participants free of clinically overt cardiovascular disease, showed 
a positive association between plasma GDF-15 and cardiometabolic risk factors (age, 
smoking, diabetes, antihypertensive treatment, renal insufficiency and use of non-steroidal 
anti-inflammatory drugs), whereas GDF-15 was negatively associated with total and high-
density lipoprotein cholesterol. The interindividual variation was partly explained by clinical 
correlates (38%) and phenotypic variation (38%)
39
. These studies point towards a possible 
role of GDF-15 in the pathophysiology of atherothrombosis.  
     In a cohort study of male subjects selected from the Swedish Population Registry, and in a 
second cohort study of same-sex twins from the Swedish Twin Registry, serum GDF-15 was 
shown to be a novel and powerful predictor of all-cause mortality in the general population 
that was independent of several markers associated with mortality risk, including age, BMI, 
smoking history, IL-6, serum CRP concentration and telomere length
52
. In the Prospective 
Investigation of the Vasculature in Uppsala Seniors (PIVUS) study, determination of GDF-15 
and the changes in its concentration over time were powerful predictors of mortality in elderly 
community-dwelling individuals; however, these changes could only be partly explained by 
cardiovascular risk factors, indicators of neurohumoral activation and inflammation, and renal 
function. This means that the prognostic importance of GDF-15 concentrations is mediated by 
cardiovascular perturbations as well as by independent but not yet elucidated pathobiological 
pathways
46
. The Uppsala Longitudinal Study of Adult Men (ULSAM) cohort study 
demonstrated that GDF-15 had the potential to predict cardiovascular death, cancer mortality 
and morbidity over the next 10 years independent of established risk factors and biomarkers 
of cardiac, renal dysfunction and inflammation
53
. Finally, in the Rancho Bernardo Study with 
1,391 older community-dwelling adults without a history of cardiovascular disease and 
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 followed for a mean of 11 years, GDF-15 was a strong predictor of all-cause and non-
cardiovascular mortality, after adjusting for traditional risk factors, CRP and N-terminal pro-
brain natriuretic peptide (NT-proBNP)
35
. Although the underlying reasons for this association 
are as yet incompletely understood, the ageing process results in a progressive increase in 
serum GDF-15 concentrations, reflecting cumulative oxidative stress, inflammation and 
replicative senescence. There is an equal contribution of genetic and environmental factors to 
the variation in the serum GDF15 concentration
52
. Disease-specific therapeutic interventions 
that reduce serum GDF-15 concentrations may lead to a decreased risk of death and increase 
longevity
51
. 
     In the Sydney Memory and Ageing Study, a community-based longitudinal study, an 
inverse association was found between serum GDF-15 concentrations and subcortical and 
cortical gray matter volumes, both cross-sectionally and longitudinally
54
. 
 
Cardiovascular diseases 
Increased circulating GDF-15 concentrations have been linked to the development and 
progression of cardiovascular pathologies, and levels of GDF-15 may be used prognostically. 
GDF-15 acts as a cardioprotective cytokine that inhibits cardiomyocyte hypertrophy, cell 
apoptosis and myocardial remodeling
7,28,55,56
. A high expression of GDF-15 is induced by 
atherosclerosis, heart failure, ischemia-reperfusion injury and cardiac hypertrophic load
57
.  
 
Heart failure 
In 2016, a systematic review
58
 investigated the utility of GDF-15 as a biomarker in heart 
failure. The analysis of 21 original studies (n = 20,920 study participants)
33,35,46,51,59-75
 showed 
that GDF-15 has added value, beyond that of traditional cardiovascular risk factors and 
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 biomarkers, in predicting all-cause mortality in heart failure patients, A multi-biomarker 
strategy with GDF-15 as one of the components may be superior to conventional risk scores
51
.  
     Increasing plasma GDF-15 concentrations have been reported along the different stages of 
heart failure
65
. The preclinical heart failure stage was characterized by significantly increased 
plasma GDF-15 concentrations and left ventricular mass index in comparison with control 
subjects; plasma GDF-15 levels could be useful to identify patients without signs of 
symptoms of heart failure yet
76
. Equal diagnostic capability for GDF-15 and NT-proBNP has 
been reported to differentiate patients with heart failure with preserved ejection fraction 
(HFpEF) and control subjects, whereas the ratio of NT-proBNP and GDF-15 provided a 
superior capacity to distinguish HFpEF subjects from patients with heart failure with a 
reduced ejection fraction (HFrEF)
65
. In addition, higher plasma GDF-15 concentrations were 
found in patients with heart failure with reduced ejection fraction (HFrEF) in comparison with 
patients with heart failure with midrange ejection fraction (HFmrEF)
76
. GDF-15 may have the 
capacity to distinguish normal diastolic function from asymptomatic diastolic dysfunction and 
increasing GDF-15 concentrations are associated with increasing severity of diastolic 
dysfunction
68
.  
     Although its exact role remains to be elucidated, GDF-15 may play a role in the 
pathophysiology of left ventricular remodeling, hypertrophy and myocardial fibrosis
77
. At 
present, it is unclear whether the GDF-15 response, which is triggered after myocardial 
damage, is inadequate to prevent disease progression or whether GDF-15 itself acts as a 
mediator of left ventricular damage
58
. 
 
Acute coronary syndrome 
After a myocardial infarction, the plasma concentration of GDF-15 increases rapidly, peaks at 
90 min and persists at an elevated concentration for up to 52 h after the onset
78
. In patients 
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 with acute coronary syndrome, no independent relationship between the GDF-15 
concentrations and the extent of myocardial damage has been observed as reflected by 
necrosis biomarkers or infarct size
27,79-81
. Unlike a rise and fall pattern of other biomarkers of 
myonecrosis, GDF-15 is characterized by a relatively stable pattern that reflects chronic 
disease burden
82
. In a meta-analysis
83
 of 8 studies (n = 8903 participants)
75,78-80,82,84-86
, high 
plasma concentrations of GDF-15 (cutoff point: 1800 ng/L) were shown to be associated with 
increased risk of mortality and recurrent myocardial infarction in patients with acute coronary 
syndrome [non-ST elevation myocardial infarction (NSTEMI) and ST elevation myocardial 
infarction (STEMI)], which means that GDF-15 could be used as an independent prognostic 
and clinically useful biomarker. In addition, increased risk for adverse left ventricular 
remodeling and hospitalization for heart failure after acute coronary syndrome has been 
reported in patients with higher GDF-15 concentrations
33,71,75
. GDF-15 has been identified as 
a promising biomarkers for risk stratification and management decisions (early invasive 
strategy in patients with GDF-15 above 1200 ng/L in comparison with non-invasive treatment 
strategy when GDF-15 is below 1200 ng/L) in the setting of acute coronary syndrome
87
.  
     Higher serum GDF-15 concentrations could indicate greater damage to the myocardium 
and increased risk of adverse remodeling
50
. The use of a cutoff point reduces the statistical 
power as levels of GDF-15 vary with cardiovascular risk. Instead of using cutoff values, the 
implementation of GDF-15 as a continuous variable in new algorithms or risk scores for 
decision support in acute coronary syndromes seems a more promising approach
22
. 
 
Kidney diseases 
Although GDF-15 is only weakly expressed along the entire nephron, a marked upregulation 
in the outer medullary collecting duct is observed in response to metabolic acidosis and 
potassium depletion. It appears that GDF-15 triggers compensatory proliferation of acid 
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 secreting collecting duct cells
88
. GDF-15 is an early mediator of the injury response in the 
kidneys that may regulate inflammation, cell survival, proliferation and apoptosis
89
. This 
cytokine can modulate renal ECM production and may also enhance cellular proliferation of 
tubular epithelial cells through the noncanonical mitogen-activated protein kinase signaling 
pathway
90
. GDF-15 may be crucial for maintaining tubular integrity by enhancing tubular 
repair
91
. Kidney damage may induce the intrarenal expression of GDF-15 expression, possibly 
by TNF and p53-dependent and -independent mechanisms
92
, which may trigger a series of 
protective responses, including activated proliferation of the tubular epithelial cells, inhibition 
of ECM protein accumulation and prevention of inflammatory cell recruitment
93
. 
 
Acute kidney injury 
Acute kidney injury (AKI) is defined as rapid deterioration in kidney function that occurs in 
hours to days. As demonstrated by multivariate regression analysis, preoperative plasma 
GDF-15 concentration and estimated glomerular filtration rates (eGFR) were predictive for 
the identification of patients at higher risk of AKI after coronary artery bypass graft
94-97
. A 
kinetic increase in plasma GDF-15 concentrations during cardiac surgery in patients 
undergoing coronary artery bypass graft associated with cardiopulmonary bypass was 
observed. During the post-operative reperfusion period, a significant positive correlation was 
found between GDF-15 and both NT-proBNP and cardiac troponin-I. A significant 
association was also demonstrated between higher pre-, per- and postoperative GDF-15 
concentrations and higher EuroSCORE values
95
. Although a strong association between GDF-
15 concentration and renal function impairment has been observed, the predictive value of 
GDF-15 for the development of AKI was independent of baseline eGFR, previous kidney 
failure or traditional risk factors of AKI. Moreover, the plasma concentration of GDF-15 was 
more discriminative than eGFR, NT-proBNP or the EuroSCORE in identifying patients at 
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 risk
94
. Also, in a retrospective, observational study in patients with acute myocardial 
infarction undergoing percutaneous coronary intervention and coronary angiography, GDF-15 
was an independent risk factor for AKI. Using Kaplan-Meier analyses, a significant 
association of baseline GDF-15 concentrations with 30-day all-cause mortality risk was 
found
98
.  
     Increased plasma GDF-15 concentrations before the development of an AKI may be a sign 
of previous subclinical kidney injury that is undetectable using routine clinical parameters. 
GDF-15 is secreted early in the phase of renal endothelial dysfunction and precedes the 
development of microalbuminuria
94,95
. 
 
Chronic kidney disease 
CKD, which is characterized by a gradual loss of kidney function, has an estimated global 
prevalence of more than 10%. In the Framingham Heart Study offspring cohort study, higher 
plasma GDF-15 concentrations were associated with incident CKD and a rapid decline in 
kidney function. Adding plasma GDF-15 to clinical covariates improved risk prediction of 
incident CKD. At present, it is still unclear whether there is an active contribution of GDF-15 
to the development of CKD, owing to its association with vascular dysfunction, or whether 
GDF-15 acts via direct kidney effects
99
. 
     In the Clinical Phenotyping and Resource Biobank (C-PROBE) study and the Seattle 
Kidney Study (SKS), a strong correlation was observed between circulating GDF-15 
concentrations and GDF-15 mRNA expression in the tubulointerstitial compartment
92
. The 
intrarenal expression of GDF-15 may prevent organ damage through controlling recruitment 
of inflammatory cells
53,89
. However, higher plasma GDF-15 concentration were associated 
with a more than 2-fold increased risk of CKD progression, independent of other risk factors 
for progression of kidney disease
92
.  
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      In two cohorts of incident dialysis patients (n = 98, Sweden; n = 381, America, follow-up: 
4 years), it was demonstrated that serum GDF-15 is an additional novel predictor of 
mortality
100
. A small prospective study of hemodialysis patients (n = 87, Turkey, follow-up: 
24 months) described the link between serum GDF-15, mortality and carotid artery 
thickening
101
. The prospective contemporary cohort of maintenance hemodialysis patients 
from the multicenter Malnutrition, Diet, and Racial Disparities in Chronic Kidney Disease 
(MADRAD) study (n = 203) confirmed the higher mortality risk in hemodialysis patients with 
high circulating GDF-15 concentrations, independent of sociodemographic and comorbidity 
characteristics. Each 1000 ng/L increase in GDF-15, or each 4000 ng/L increase (1 standard 
deviation) was associated with a 17-18% or a 50% higher mortality risk, respectively
102
. 
Higher serum GDF-15 concentrations are also reported in dialyzed children (n = 19 
hemodialysis and 22 peritoneal dialysis patients), with lower levels in children on peritoneal 
dialysis in comparison with those on hemodialysis. Inflammatory and stress-responsive 
aspects of GDF-15 may explain the discrepancy in levels between the hemodialysis and 
peritoneal dialysis patients
103
. 
     At present, the underlying mechanisms by which GDF-15 adversely influences survival of 
hemodialysis patients remain undefined. On the one hand, GDF-15 may play a prominent role 
in the pathogenesis of atherosclerosis and vascular thrombosis
104,105
. On the other hand, 
apoptotic, antihypertrophic and anti-inflammatory actions have been described for GDF-
15
55,106
. GDF-15 is significantly related to anorexia, hypoalbuminemia and decreasing BMI, 
which are strong predictors of cardiovascular death in CKD. Direct action of GDF-15 upon 
the hypothalamus to reduce food intake and energy expenditure has been described
107
. In 
animal models, the administration of anti-GDF-15 neutralizing antibodies reversed or 
prevented GDF-15 induced satiety and weight reduction
12,13
. Future research should focus on 
the sources of GDF-15 production in end stage renal disease patients
102
. 
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 Diabetic nephropathy 
Conflicting results have been published regarding the role of GDF-15 as a risk marker of 
diabetic nephropathy, which partly may be due to differences in kidney function, event rates 
and adjustments
108
. On the one hand, several studies suggest that a higher amount of GDF-15 
is an independent risk marker for diabetic nephropathy in type 2 diabetes mellitus patients 
from early to late stages of dysfunction. In the prospective case-control study, selected from 
the Prevention of Renal and Vascular Endstage Disease (PREVEND) cohort (n = 33, follow-
up: 3 years), GDF-15 was a clinically valuable marker, beyond conventional risk markers, for 
predicting transition in albuminuria stage. Prior to transition, significantly higher plasma 
GDF-15 concentrations were found in diabetic patients in comparison with the control group 
(type 2 diabetes mellitus patients with persistent normoalbuminuria or microalbuminuria).  
Potentially GDF-15 could be a valuable marker for individual risk stratification, to facilitate 
the start or intensification of treatment in high-risk patients to prevent or delay the progression 
of nephropathy
109
. As endothelial cells appear to be a prominent source of GDF-15, the 
circulating amount of GDF-15 most likely represents generalized endothelial and 
microvascular damage, which is also reflected by the presence of albuminuria
54,110
. In 
addition, GDF-15 may reflect the relative age of the vasculature and its ability to resist 
leakage of albumin
39
. In the prospective European Rational Approach for the Genetics of 
Diabetic Complications (EURAGEDIC) project, which included 451 type 1 diabetic patients 
with diabetic nephropathy and a control group of 440 patients with longstanding type 1 
diabetes and persistent normoalbuminuria (follow-up: 8 years), higher plasma GDF-15 
concentrations predicted all-cause mortality in diabetes mellitus type 1 patients with and 
without diabetic nephropathy. In addition, higher plasma GDF-15 concentrations 
independently predicted cardiovascular mortality and morbidity as well as deterioration of 
kidney function in patients with diabetic nephropathy, after adjustment for conventional 
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 cardiovascular disease and renal risk factors. These findings could be explained by several 
underlying conditions, including acute/or chronic ischemia, associated with adverse 
cardiovascular outcomes. GDF-15 may not only be a marker of ongoing tissue damage but 
also may actively influence multiple downstream signaling effectors as part of a 
cardioprotective mechanism
111
.
 
     On the other hand, in a prospective study in type 2 diabetes mellitus patients (n = 200, 
75.5% male) without cardiac disease but with microalbuminuria, plasma GDF-15 was 
independently associated with all-cause mortality and a eGFR decline > 30%, but it did not 
predict cardiovascular disease after adjustment for traditional risk factors
108
. In the post-hoc 
analysis of the sulodexide macroalbuminuria (Sun-MACRO) trial, the value of GDF-15, high 
sensitivity troponin T (hs-TnT) and NT-proBNP was investigated to predict cardiovascular 
and renal complications in type 2 diabetes mellitus patients with diabetic nephropathy (n = 
861). In a multiple regression model, GDF-15 was a modest predictor of renal events but not 
of cardiovascular events. The renal risk prediction did not improve beyond currently 
established risk markers
112
. 
 
Light chain amyloidosis 
Light chain amyloidosis, the most common form of systemic amyloidosis, is caused by 
protein misfolding. It is characterized by extracellular deposits of insoluble fibrils in different 
organs and tissues. The role of GDF-15 as a biomarker for renal outcome and survival in 
patients with light chain amyloidosis has been investigated as GDF-15 improves the 
prediction of prognosis in both renal and cardiovascular diseases. In two independent cohorts 
with untreated and newly diagnosed light chain amyloidosis (n = 107 + 202), a positive 
association was observed between serum GDF-15 concentrations (cutoff level: 7575 ng/L) 
and risk of early mortality and poor overall survival, independently of NT-proBNP and hs-
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 TnT or high sensitivity troponin I concentrations. Patients with a GDF-15 concentration ≥ 
4000 ng/L had a high risk for progression to dialysis, independently of renal risk which was 
defined by eGFR and proteinuria
113
.  
     The high concentration of GDF-15 may be a marker of cardiac stress and also may reflect 
systemic free light chain-related proteotoxic stress with involvement of reactive oxygen 
species
114
. This could be due to the direct effects of the toxic amyloidogenic light chains, but 
also to the systemic inflammatory state seen in chronic heart failure. In this way, GDF-15 may 
provide incremental prognostic information. A reduction of GDF-15 during therapy was 
associated with better survival and renal outcomes
113
. Mesenchymal, endothelial or even 
tubular cells located in the kidneys may produce GDF-15 in response to the toxic effects of 
amyloid fibrils
114
 or to proteotoxic stress caused by the free light chains
115
. 
 
Idiopathic membranous nephropathy 
Nephrotic syndrome is characterized by excessive protein loss in urine, and 20 - 30% of cases 
are caused by idiopathic membranous nephropathy. Currently, there is no biomarker to predict 
the prognosis in the long term for idiopathic membranous nephropathy. In a  study of 35 
biopsy-proven idiopathic membranous nephropathy patients (mean follow-up: 44.1 months), a 
serum GDF-15 concentration of 2150 ng/L was the best cut-off value (sensitivity: 75.0%, 
specificity: 82.1%) to predict disease, as defined by a 30% decline in eGFR or the 
development of end-stage renal disease, after adjusting for additional risk factors. A positive 
correlation was observed between anti-phospholipase-A2-receptor autoantibodies and GDF-
15. The study suggested that the elevated GDF-15 concentration demonstrates advanced renal 
injury and a high degree of proteinuria in patients with idiopathic membranous nephropathy, 
and these conditions cause rapid progression of the disease
116
. 
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 IgA nephropathy 
GDF-15 could be considered as an integrated prognostic factor of IgA nephropathy, 
correlating with eGFR and the urinary protein creatinine ratio. In 212 patients with biopsy-
proven IgA nephropathy, a serum GDF-15 cut-off value of 496 ng/L showed a 90% 
sensitivity and 73% specificity to predict the need for hemodialysis within 2 years. A GDF-15 
value > 490 ng/L predicted a decline in eGFR > 30 mL/min within 1 year of follow-up, with a 
sensitivity of 64% and a specificity of 65%. Moreover, a positive correlation was observed 
between higher serum GDF-15 concentrations and the extent of interstitial fibrosis/tubular 
atrophy in biopsy samples. Future studies should further investigate the direct or indirect renal 
effects of GDF-15 in IgA nephropathy patients
117
. 
 
Liver diseases  
The expression of GDF-15 is rapidly and dramatically upregulated following surgical and 
chemical injury and heat shock that cause acute liver injury and regeneration
8
. The induction 
of GDF-15 is an immediate early response to liver injury that can occur through the TNF and 
p53 independent pathways
118
. Direct liver injury can induce GDF-15 expression in 
hepatocytes in the absence of other cell types such as inflammatory cells. The exact 
mechanistic role of GDF-15 in liver disease has not yet been clarified. In a study on GDF-15 
knock-out mice, the authors suggested either that GDF-15 had no regulatory role in liver 
injury and regeneration, or that its hepatic function could be compensated by other secreted 
growth factors or by other regulatory pathways
8
.  
 
Non‐alcoholic fatty liver disease and non-alcoholic steatohepatitis 
Non-alcoholic fatty liver disease (NAFLD), the most common liver disease, is characterized 
by an excess of fat stored in the liver. NAFLD that is complicated by liver cell damage and 
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 inflammation is called non-alcoholic steatohepatitis (NASH), and it can lead to liver fibrosis 
and cancer.  
     Elevated expression of GDF-15 has been detected in livers of NASH animal modes, due to 
diet induced hepatic ER stress. GDF-15-knock-out mice showed more severe phenotypes with 
more steatosis, fibrosis, inflammation, metabolic dysregulation or liver injury. Expression of 
endogenous GDF-15 seems to be a protective mechanism to prevent further progression of 
NASH and related metabolic disorders by direct suppression of fibrosis-related genes and 
osteopontin in hepatic stellate cells. GDF-15-induced improvement of steatosis and 
inflammation may be due to increased fatty acid oxidation in hepatocytes and reduced 
macrophage recruitment
119
. GDF-15 exerts a critical role in lipid homeostasis. In a mouse 
model, GDF-15 expression was shown to be associated with cellular ER stress in the face of 
excess lipid accumulation and hepatic steatosis. Cellular oxidative stress could initiate hepatic 
ER stress, which could positively regulate GDF-15 expression through activation of its 
transcriptional activity by C/EBP-homologous protein (CHOP). In this way, GDF-15 could 
act as a direct downstream target in the unfolded protein responses program. Enhancing fatty 
acid β-oxidation to supply ketones for peripheral tissues and organs and relieving ER stress in 
the liver with NAFLD of high fat diet-feeding mice enforced expression of hepatic GDF-15 
could alleviate hepatic steatosis and hepatitis
120
. GDF-15 expression is driven by the IRE1α-
XBP1s branch
121
.  
     Based on the findings in animal studies, GDF-15 has been suggested as a potential 
innovative therapeutic target in patients with NASH
119
 as well as alcohol-induced liver 
injury
122
. However, another study suggested that GDF-15 treatment increased fibrotic gene 
expression
123
, which may be explained by the study design (no stimulation with TGF-β). 
     GDF-15 has been identified as a novel biomarker of lobular inflammation, ballooning and 
fibrosis in NAFLD. Significantly higher serum GDF-15 concentrations were reported in 
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 NASH patients in comparison with healthy controls and patients with NAFLD. Serum GDF-
15 concentrations showed a step-wise association with the fibrosis stage, with significantly 
higher values in advanced stages of fibrosis (≥ F3) in comparison with stages F0-2. In patients 
with NAFLD, the highest quartile of serum GDF-15 concentrations showed a significant 
positive association with the risk of advanced stage fibrosis, even after adjustment for other 
metabolic risk factors. This suggests that GDF-15 could be used as one of the criteria for liver 
biopsy indication. There was no proven association with the risk of NASH
124
.  
     Although there is the suggestion that GDF-15 participates in the early response to liver 
injury or inflammation by increasing phosphorylation of SMAD2 and SMAD3, a recent report 
showed that possible contamination of some batches of recombinant GDF-15 with TGF-β 
may explain this finding
125
. Advanced fibrosis in NAFLD, which is a chronic progressive 
disease, shows a strong association with serum GDF-15 concentrations. The chronically 
elevated serum GDF-15 concentration, the origin of which has not been identified, has been 
suggested to affect hepatic fibrosis or inflammation in a liver-independent manner. Another 
hypothesis is that the increase in GDF-15 may be an adaptation mechanism for liver injury
124
. 
     The clinical usefulness of GDF-15 as a novel biomarker for predicting advanced fibrosis 
requires confirmation in large-scale prospective replication studies. The causal relationship 
between GDF-15 and development of advanced fibrosis in NAFLD should also be further 
investigated
124
. 
  
Liver cirrhosis 
Liver cirrhosis is a condition in which liver tissue is replaced by scar tissue, leading to 
impairment of function. GDF-15 has been put forward as a predictive biomarker of liver 
fibrosis and severity in patients with chronic liver disease. As a result of chronic damage to 
hepatocytes, prolonged stimulation of hepatic stellate cells results in the release of 
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 profibrogenic abundant factors such as GDF-15, leading to the development of liver cirrhosis. 
In a cohort study of 834 European individuals (age 17-84 years, males 61%) with viral (n = 
559) and non-viral (n = 275) chronic liver diseases, a three-marker algorithm (placental 
growth factor = 20.2 ng/L, GDF-15 = 1582 ng/L and hepatic growth factor = 2598 ng/L) 
identified an additional 50% of patients with chronic liver diseases at risk for progressed 
fibrosis who presented with low elastography values
126
. A multicenter retrospective study 
found significantly elevated serum GDF-15 concentrations in Asian subjects with liver 
cirrhosis (60 cases, mean age: 50 years, 42% males) in comparison with healthy subjects (183 
cases, mean age: 50 years, 50.3% males). At the optimal cut-off point of 2463 ng/L, GDF-15 
had a moderate sensitivity (63.1%) and a high specificity (86.6%) for patients with liver 
cirrhosis in comparison with hepatitis B virus or hepatitis C virus (HCV) carriers
127
. 
     In a case-control study, serum GDF-15 concentrations were significantly higher in patients 
with chronic liver diseases than in the control group. Patients with decompensated liver 
cirrhosis (n = 47) had augmented serum GDF-15 concentrations in comparison with subjects 
with chronic hepatitis (n = 54) and compensated cirrhosis (n = 44). Receiver operating 
characteristic curves showed the highest sensitivity (97.9%) and specificity (94.1%) of GDF-
15 to distinguish between patients with compensated and decompensated liver cirrhosis at a 
cutoff value of 869 ng/L, which is clinically critical. The fibrosis level rather than 
hepatocellular damage from the infection appeared to be the underlying reason for the 
increased GDF-15 concentrations
128
.  
 
Hepatitis C infection 
In comparison with healthy subjects, carriers of HCV were characterized by elevated serum 
GDF-15 concentrations, probably by viral agents, host stress/injury, or both. Elevated GDF-
15 potentially regulates both HCV replication and host hepatocellular carcinoma-related 
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 signaling pathways and genes. GDF-15 is a circulating cytokine that may function by 
transducing signals to target cells through the endocrine, autocrine and paracrine systems. In 
vitro studies showed that elimination of endogenous GDF-15 led to arrest of HCV replication, 
whereas the application of exogenous GDF-15 resulted in augmented JFH-1 based HCV cell 
culture virus replication in cultured hepatoma cells, augmented cell proliferation, DNA 
production and increased invasion of the cells. GDF-15 overexpression was associated with 
significant phosphorylation of Akt/GSK-3b. In conclusion, GDF-15 may be a potential 
biomarker and interventional target
129
. 
 
Metabolic syndrome 
GDF-15 has been identified as a coordinator of the energy metabolism. Macrophages of the 
stromal vascular fraction and adipocytes in white adipose tissue release GDF-15, which acts 
as an adipokine
130
. Obesity, a chronic inflammatory state, promotes the activation of p53 in 
adipose tissue, leading to increased production of proinflammatory cytokines that induce the 
expression of GDF-15
131
. 
     In a transgenic mice model, long-term increased expression of GDF-15 was associated 
with decreased food intake, body weight and adiposity with concomitantly improved glucose 
tolerance, both under normal and obesogenic dietary conditions
132
. In addition, in vivo 
application of GDF-15 in ob/ob mice increased insulin sensitivity and promoted weight loss, 
as a result of increased mobilization of free fatty acids and augmented oxidative metabolism 
in muscles, liver and adipose tissue. The transcriptional activation of GDF-15 was achieved 
by p38 kinase activation of CHOP. OxPhos dysfunction in skeletal muscle increased the 
production of GDF-15, which transmitted a systemic mitohormetic adaptation and 
redistribution of energy stores. GDF-15 could be a potent treatment target of obesity-related 
diseases, although the precise molecular mechanisms by which GDF-15 exerts its effects on 
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 obesity remain to be elucidated. In obese subjects, the induction of GDF-15 is the result of 
compensation for muscle mitochondrial dysfunction. This is a physiological response that 
aims to reestablish metabolic homeostasis
133
. 
 
     In another mice model of diet-induced obesity with GDF-15 KO mice and wild-type 
controls on a high fat diet, endogenous GDF-15 had a protective role in obesity development. 
Although not essential in maintaining basic life functions, lack of GDF-15 was associated 
with progression of obesity and pathological conditions. GDF-15 KO mice had lower 
locomotor activity, which was associated with a reduced energy expenditure and was a 
contributing factor to the lower metabolic rate. Further studies should investigate if GDF-15 
deficiency also affects thermoregulation and basal metabolism. The increased concentrations 
of GDF-15 observed in obesity may be the result of a response to overcome GDF-15 
resistance
134
. Based on these data
131-133
, GDF-15 may have therapeutic potential for treatment 
of obesity and prediabetic glucose intolerance. 
     As demonstrated in a small study of 20 women with anorexia nervosa, 28 obese women 
and 28 healthy normal-weight female controls, hyperinsulinemia was associated with 
significantly higher serum GDF-15 concentrations in different states of adiposity
135
. The 
upregulation of GDF-15 in both extreme cachexia and morbid obesity may be the result of 
oxidative stress in adipocytes and other issues. In addition, nutrient availability (high glucose 
concentrations) and weight loss (inducing compensatory changes in appetite-regulatory 
mechanisms) may modify GDF-15 secretion, either by using hormonal or neural mechanisms 
or by acting on different organs
136
. In a cross-sectional cohort of obese and lean women, 
women with obesity had significantly increased serum GDF-15 concentrations in comparison 
with normal weight healthy women
137
. A case-control study of 20 obese patients (75% 
female) with metabolic syndrome and 20 obese apparently healthy control subjects showed 
higher serum concentrations of GDF-15 in patients with metabolic syndrome
138
. Increased 
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 plasma GDF-15 concentrations were also measured in a cohort of 118 morbidly obese patients 
in comparison with 30 age- and sex-matched healthy lean individuals. A positive correlation 
was observed between GDF-15 and age, waist-to-height ratio, mean arterial blood pressure, 
triglycerides, creatinine, glucose, insulin, C-peptide, hemoglobin A1c and the homeostatic 
model assessment insulin resistance index, whereas a negative correlation was observed with 
oral glucose insulin sensitivity. However, after bariatric surgery (Roux-en-Y gastric bypass), a 
significant decline in weight, leptin, insulin and insulin resistance was accompanied by 
increased plasma GDF-15 levels. The pathophysiological mechanisms that control 
postoperative GDF-15 concentrations remain unknown
139
. Serum GDF-15 concentrations 
were not significantly different between normal-weight and obese children. In contrast to 
adults, children may have a much shorter duration of obesity and inflammation to develop 
metabolic disturbances, which could influence GDF-15 concentrations. The main source of 
GDF-15 remains to be established in children
140
. 
 
     Polycystic ovary syndrome (PCOS), a disorder characterized by menstrual abnormalities, 
subfertility, and hyperandrogenism, is associated with the metabolic syndrome. No significant 
differences in plasma GDF-15 concentrations were found between obese patients with PCOS, 
patients with idiopathic hirsutism and healthy controls that were matched for age and 
BMI
141,142
. 
     With the identification of GFRAL as the high-affinity receptor for GDF-15, the GDF-15-
GFRAL-RET receptor signaling complex may be a particularly attractive target for obesity 
therapy
25,143
. GDF-15 acts through a vagus-nerve mediated mechanism. It has been 
demonstrated that the body weight of obese mice and monkeys can be lowered (~10–24%) by 
daily treatment with murine and human recombinant GDF-15 for 4-6 week. By developing a 
Fc fusion protein based on an X-ray structure of GDF-15, the short biological half-life of this 
protein can be prolonged
144
. Future research should focus on the question of why 
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 concentrations of GDF-15 are increased in obesity, whereas the injection of GDF-15 leads to 
weight loss
145
.
 
 
Diabetes mellitus 
Multiple studies have investigated the effects and pathways whereby GDF-15 affects glucose 
metabolism and body weight
25,36,132,136,137,139
. Studying serum GDF-15 concentrations in slim 
and obese people after various meals and fasting state showed increased secretion of GDF-15 
in case of high glucose intake and insulin levels. This effect was mediated by rapid glucose 
and insulin escalation after intake of fast digestible carbohydrates and was independent of the 
number of calories. The different time-dependent peaks of secreted GDF-15 concentrations 
for glucose and insulin suggest that different mechanisms stimulate the transcription and 
release of GDF-15, with a common pathway or endpoint. The divergent regulation of GDF-15 
transcription and release is characterized by downregulation of transcription after 24 h, while 
the release is still stimulated. Post-transcriptional factors (mRNA stability or intracellular 
storage of mature GDF-15) may influence the systemic regulation of GDF-15. During short-
term fasting, a decline in the serum GDF-15 concentrations has been observed
136
. Based on 
ROC curve analysis, GDF-15 as a biomarker for impaired fasting glucose has a cutoff value 
of 510 ng/L in males and 400 ng/L in females. Serum GDF-15 concentration was lowest in 
patients without diabetes mellitus, intermediate in subjects with prediabetes and highest in 
type 2 diabetes mellitus patients
146
. In patients with impaired glucose tolerance, significantly 
higher serum GDF-15 levels have been detected in comparison to those with normal glucose 
tolerance
147
. 
     The XENical in the prevention of Diabetes in Obese subjects (XENDOS) trial included 
496 obese nondiabetic individuals (median age: 48 years, 52% men) who were followed for 4 
years. Baseline plasma GDF-15 levels were related to abdominal obesity and the homeostasis 
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 model assessment of insulin resistance (HOMA-IR) and were independently associated with 
future insulin resistance and abnormal glucose control
36
. In the Malmö Diet and Cancer-
Cardiovascular Cohort, an urban population of 4360 individuals without diabetes mellitus 
(mean age 57.4 ± 5.96 years, 38.6% men) was followed for 19 years. It was demonstrated that 
circulating GDF-15 could be a useful biomarker to identify people (especially those ≤ 60 
years old) with a risk of incident diabetes mellitus, after controlling for traditional risk 
factors
148
. The increased expression of GDF-15 may occur in response to inflammation that 
precedes diabetes. This upregulation, which occurs in a p53-dependent manner, is not 
sufficient to compensate for the chronic low-grade inflammation that leads to metabolic 
disorders such as β cell dysfunction and insulin resistance149-151. In a prospective study in 746 
patients with type 2 diabetes mellitus followed for 60 months, GDF-15 was, in the 
combination with NT-proBNP and hs-TnT, a strong predictor of death or incidental 
hospitalization for cardiovascular disease
152
. Also, in a small study of 107 type 2 newly 
diagnosed Asian diabetes mellitus patients, serum GDF-15 concentration showed an 
independent association with the future risk for cardiovascular disease
153
. GDF-15 could have 
the capacity to protect endothelial cells against glucose induced injury by activating PI3-
kinase/AKT/eNOS
154
.  
     The Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial analyzed a total 
of 237 biomarkers in 8,401 individuals (27.6% treated with metformin). GDF-15 was 
identified as a novel biomarker for the use and dose of metformin that could provide 
information about its mechanism of action and effect on outcomes
155
.  
 
Sepsis 
Although increased blood concentrations of GDF-15 have been demonstrated in multiple 
chronic diseases, its role as a biomarker in critically ill patients, especially in sepsis and septic 
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 shock, should be further investigated. Based on the findings of two studies
156,157
, the 
prognostic role of GDF-15 was explored in a case-control study [219 critically ill patients 
(146 with sepsis, 73 without sepsis) and 66 healthy controls]. Increased serum GDF-15 
concentrations in critically ill patients were associated with sepsis, organ failure and disease 
severity. In addition, high levels of GDF-15 at intensive care unit admission were associated 
with the prediction of short- and long-term risk of mortality, especially in patients with 
sepsis
158
.  
     A link between increased plasma GDF-15 concentrations and decreased muscle microRNA 
expression may explain the muscle atrophy of intensive care unit-acquired weakness
159
. The 
increased expression of GDF-15 in intensive care unit patients may also reflect macrophage 
activation and proinflammatory processes
1
. GDF-15 may function as a tissue protective 
molecule, blocking cell death pathways and inducing regeneration
55
. Finally, the pro- or 
antiproliferative properties of GDF-15 may influence long-term survival
158
. 
 
Iron metabolism and anemia 
GDF-15 has been identified as an important regulator of iron homeostasis and 
erythropoiesis
160
 (for a review, see
161
). In the late stage of differentiation of erythroid 
progenitor cells, apoptosis of erythroblasts is associated with upregulation of GDF-15
161
. 
Pathophysiologic changes in iron availability can induce increased expression of GDF-15. In 
a range of human cell lines, iron depletion resulted in increased amounts of GDF-15 mRNA 
and secreted proteins
162
. However, comparing serum GDF-15 values in iron deficiency 
anemia (IDA), anemia of chronic disease (ACD) and ACD subjects with true iron deficiency 
(ACD/IDA) showed significantly increased concentrations in ACD and ACD/IDA, but not in 
IDA in comparison with control subjects. No correlation was observed between GDF-15 and 
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 hepcidin. During inflammatory conditions, the immune mediated induction of GDF-15 may 
not primarily affect hepcidin expression and iron homeostasis
163
.  
     In cases of ineffective erythropoiesis, high expression of GDF-15 induces incomplete 
suppression of hepcidin and increases iron absorption despite iron overload. Serum GDF-15 
concentrations are remarkably high in patients with acquired sideroblastic anemias (up to 
5000 ng/L), congenital dyserythropoiesis (up to 10,000 ng/L) and thalassemia syndromes (up 
to 100,000 ng/L)
164
. A significant association between the rs4808793 polymorphism of the 
GDF-15 gene and serum GDF-15 concentrations in β-thalassemia subjects has been 
reported
165
.  
     In early stages of CKD, significantly higher serum GDF-15 concentrations have been 
detected in patients with anemia
166
, indicating ineffective erythropoiesis and increased 
erythroid activity. Although significant elevated serum GDF-15 concentrations were 
documented in hemodialysis patients, no correlation between GDF-15 and markers of the iron 
metabolism was found
167
. In a study of 62 prevalent kidney allograft recipients, significantly 
higher serum GDF-15 levels were reported in comparison with healthy volunteers. No 
relationship between GDF-15, serum iron or ferritin was demonstrated. In a multivariate 
analysis, hepcidin was a predictor of GDF15
168
. This finding was confirmed in heart 
transplant patients
169
. The precise interaction between GDF-15 and hepcidin should be further 
investigated. 
 
Conclusions 
Increased serum concentrations of GDF-15 are associated with different types of organ 
failure. Depending on the state of cells and the microenvironment, diverse and partially 
opposing functions are described for GDF-15. GDF-15 may add prognostic information 
independent of traditional cardiac and renal biomarkers. Combining GDF-15 with other 
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 biochemical markers and imaging methods may improve diagnosis and prognosis. Prospective 
controlled studies are needed to elucidate the causal implications of GDF-15 and whether this 
cytokine represents a novel therapeutic target for cardiovascular and metabolic health. More 
experimental and clinical studies are also necessary to characterize cellular release 
mechanisms and to identify the main source of this anti-inflammatory cytokine. 
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 Legend to figure 
Figure 1. Overview of the growth differentiation factor 15 (GDF-15) signaling pathways, 
explaining its apoptotic, antihypertrophic and anti-inflammatory actions. 
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 Table 1: Characteristics of studies investigating the potential value of GDF15 as a 
biomarker in the general population 
Study General characteristics GDF15-assay 
Dallas Heart Study
47
 Single-site, multiethnic, 
population-based probability 
sample 
n = 3219, age: 30-65 years (mean 
age: 44 years), 55% women, 49% 
black, median follow-up: 7.3 
years 
Sandwich platform (LOD: 10 
ng/L, maximum cutoff: 7500 
ng/L, within-assay CV: 6%, 
interassay CV: 9%) 
Danish-Multinational 
MONitoring of trends 
and determinants in 
Cardiovascular disease 
(DAN-MONICA)
48
 
Cohort study 
n = 3785, age: 30-60 years, 
measurements at 45.5, 50.2 and 
55.6 years of age, median follow-
up: 27 years 
Abbott ARCHITECT assay 
(range: 0-5000 ng/L, LOD: 5 
ng/L. Interassay CV: 4.68%, 
intra-assay CV: 2.20% at a 
GDF-15 concentration of 500 
ng/L) 
Women’s Health 
Study
49
 
Case-control study 
n = 514 , age: ≥ 45 years (mean 
age: 60 years), 100% women, 
follow-up: 4 years 
Sandwich ELISA 
Framingham Heart 
Study
50
 
Cohort study 
n = 3428, mean age: 59 years, 
53% women, mean follow-up: 
11.3 years 
ECLIA (LOD: < 10 ng/L, a 
linear measuring range up to 20 
000 ng/L, interassay 
imprecisions of 2.3% and 1.8% 
at GDF-15 concentrations of 
1100 and 17 200 ng/L) 
Framingham Offspring 
Study + Prospective 
Investigation of the 
Vasculature in Uppsala 
Seniors (PIVUS) 
study
39
 
Cohort study 
n = 2991, mean age: 59 years, 
56% women 
n = 878, mean age: 70 years, 
51% women 
ECLIA (LOD: < 10 ng/L, a 
linear measurement interval up 
to 20 000 ng/L, interassay 
imprecisions of 2.3% and 1.8% 
at GDF-15 concentrations of 
1100 ng/L and 17 200 ng/L) 
Swedish Population Cohort study Sandwich ELISA (CV < 12%) 
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 Registry +  Swedish 
Twin Registry
52
 
n = 876, 100% men, age: 46-80 
years (median age: 68 years), 
median follow-up: 5.3 years 
n = 324, 69% women, age: 63-93 
years (median age: 79 years), 
median follow-up: 9.1 years 
Prospective 
Investigation of the 
Vasculature in Uppsala 
Seniors (PIVUS) 
study
46
 
Cohort study 
n = 1004 (baseline) and n = 813 
(after 5 year), 50% men, 
measurements at 70 and 75 years 
of age, follow-up: 5 years 
IRMA (LOD: 20 ng/L, assay is 
linear from 200 to 50 000 ng/L 
and has intra- and interassay 
imprecisions of 12.2%) 
Uppsala Longitudinal 
Study of Adult Men 
(ULSAM) study
53
 
Cohort study 
n = 940, age: measurements at 71 
years of age, 100% men, median 
follow-up: 9.8 years 
ECLIA (inter-assay CV: 2.3% 
at 1100 ng/L and 1.8% at 
17200 ng/L, an intra-assay CV: 
0.8% at 1100 ng/L and 0.9% at 
18600 ng/L, and a LOD of 10 
ng/L) 
Rancho Bernardo 
Study
35
 
Cohort study 
n = 1391, 61% men, mean age: 
71 years, mean follow-up: 11 
years 
Luminex platform with a 
sandwich immunoassay 
(measurable range: 2-10 000 
ng/L; LOD: 2 ng/L; limit of 
quantification, 11 ng/L). Intra-
assay CV: 
7% and interassay CV: 10% at 
a GDF-15 concentration of 
1950 ng/L 
Sydney Memory and 
Ageing Study
54
 
Cohort study 
n = 1067, 53% women, age: 70-
90 years, follow-up: 2 years 
Sandwich ELISA (CV < 10%) 
 
Abbreviations: CV: coefficient of variation, ECLIA: electrochemiluminescence 
immunoassay, ELISA: enzyme-linked immunosorbent assay, IRMA: immunoradiometric 
assay, LOD: limit of detection 
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